Effects of a Water, Sanitation, and Hygiene Mobile Health Program on Diarrhea and Child Growth in Bangladesh: A Cluster-randomized Controlled Trial of the Cholera Hospital-based Intervention for 7 Days (CHoBI7) Mobile Health Program.
diarrhea
child growth
mobile health
randomized controlled trial
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
received:
12
03
2020
accepted:
27
07
2020
pubmed:
8
8
2020
medline:
11
11
2021
entrez:
8
8
2020
Statut:
ppublish
Résumé
The Cholera Hospital-Based Intervention for 7 Days (CHoBI7) mobile health (mHealth) program was a cluster-randomized controlled trial of diarrhea patient households conducted in Dhaka, Bangladesh. Patients were block-randomized to 3 arms: standard message on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (no home visits); and health facility delivery of CHoBI7 plus 2 home visits and mHealth. The primary outcome was reported diarrhea in the past 2 weeks collected monthly for 12 months. The secondary outcomes were stunting, underweight, and wasting at a 12-month follow-up. Analysis was intention-to-treat. Between 4 December 2016 and 26 April 2018, 2626 participants in 769 households were randomly allocated to 3 arms: 849 participants to the standard message arm, 886 to mHealth with no home visits arm, and 891 to the mHealth with 2 home visits. Children <5 years had significantly lower 12-month diarrhea prevalence in both the mHealth with 2 home visits arm (prevalence ratio [PR]: 0.73 [95% confidence interval {CI}, .61-.87]) and the mHealth with no home visits arm (PR: 0.82 [95% CI, .69-.97]). Children <2 years were significantly less likely to be stunted in both the mHealth with 2 home visits arm (33% vs 45%; odds ratio [OR]: 0.55 [95% CI, .31-.97]) and the mHealth with no home visits arm (32% vs 45%; OR: 0.54 [95% CI, .31-.96]) compared with children in the standard message arm. The CHoBI7 mHealth program lowered pediatric diarrhea and stunting among diarrhea patient households. NCT04008134.
Sections du résumé
BACKGROUND
The Cholera Hospital-Based Intervention for 7 Days (CHoBI7) mobile health (mHealth) program was a cluster-randomized controlled trial of diarrhea patient households conducted in Dhaka, Bangladesh.
METHODS
Patients were block-randomized to 3 arms: standard message on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (no home visits); and health facility delivery of CHoBI7 plus 2 home visits and mHealth. The primary outcome was reported diarrhea in the past 2 weeks collected monthly for 12 months. The secondary outcomes were stunting, underweight, and wasting at a 12-month follow-up. Analysis was intention-to-treat.
RESULTS
Between 4 December 2016 and 26 April 2018, 2626 participants in 769 households were randomly allocated to 3 arms: 849 participants to the standard message arm, 886 to mHealth with no home visits arm, and 891 to the mHealth with 2 home visits. Children <5 years had significantly lower 12-month diarrhea prevalence in both the mHealth with 2 home visits arm (prevalence ratio [PR]: 0.73 [95% confidence interval {CI}, .61-.87]) and the mHealth with no home visits arm (PR: 0.82 [95% CI, .69-.97]). Children <2 years were significantly less likely to be stunted in both the mHealth with 2 home visits arm (33% vs 45%; odds ratio [OR]: 0.55 [95% CI, .31-.97]) and the mHealth with no home visits arm (32% vs 45%; OR: 0.54 [95% CI, .31-.96]) compared with children in the standard message arm.
CONCLUSIONS
The CHoBI7 mHealth program lowered pediatric diarrhea and stunting among diarrhea patient households.
CLINICAL TRIALS REGISTRATION
NCT04008134.
Identifiants
pubmed: 32761174
pii: 5881860
doi: 10.1093/cid/ciaa754
pmc: PMC8563223
doi:
Substances chimiques
Water
059QF0KO0R
Banques de données
ClinicalTrials.gov
['NCT04008134']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2560-e2568Subventions
Organisme : United States Agency for International Development
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet Infect Dis. 2018 Nov;18(11):1211-1228
pubmed: 30243583
Appl Environ Microbiol. 2001 Jul;67(7):3328-30
pubmed: 11425764
BMC Public Health. 2019 Jul 31;19(1):1028
pubmed: 31366398
Lancet. 2008 Jan 19;371(9608):204
pubmed: 18207015
Emerg Infect Dis. 2016 Feb;22(2):233-41
pubmed: 26811968
Public Health Nutr. 2012 Sep;15(9):1746-54
pubmed: 22717058
Lancet Glob Health. 2018 Mar;6(3):e316-e329
pubmed: 29396219
Lancet Glob Health. 2015 Nov;3(11):e701-11
pubmed: 26475017
Pediatrics. 2010 Mar;125(3):e473-80
pubmed: 20156903
Lancet Glob Health. 2018 Mar;6(3):e302-e315
pubmed: 29396217
Trop Med Int Health. 2018 May;23(5):508-525
pubmed: 29537671
PLoS Negl Trop Dis. 2018 Jul 27;12(7):e0006641
pubmed: 30052631
Am J Trop Med Hyg. 2016 Feb;94(2):428-36
pubmed: 26728766
Am J Trop Med Hyg. 2017 Jun;96(6):1382-1387
pubmed: 28719281
Clin Infect Dis. 2009 Nov 15;49(10):1473-9
pubmed: 19842974
Lancet Glob Health. 2019 Jan;7(1):e132-e147
pubmed: 30554749
Emerg Infect Dis. 2015 Nov;21(11):2006-13
pubmed: 26484778
PLoS Med. 2013;10(1):e1001362
pubmed: 23349621